The UK’s medicines regulator has approved the first vaccine against respiratory syncytial virus (RSV) in older adults.
The virus typically causes cold-like symptoms, but is a leading cause of pneumonia in infants and elderly people, with infections in older adults accounting for about 8,000 deaths, 14,000 hospitalisations and 175,000 GP appointments in the UK each year – more than influenza during a typical winter season.
